Jacob Corn
Professor of Genome Biology
Organization
ETH Zurich
About Jacob Corn
Jacob Corn is the Professor of Genome Biology at ETH Zurich (Zurich, Switzerland). In addition to the professorship, he is leading the Unbiased Discovery of Heterogeneous DNA Repair Preferences project.
Corn earned a BS in biology from the University of Puget Sound (Tacoma, US) in 2001 and a PhD in molecular and cell biology from the University of California, Berkeley (UC Berkeley; US) in 2007. His career has bridged academia and industry, working in therapeutic areas that include infectious disease, neurobiology, and oncology. Corn’s graduate studies at UC Berkeley with James Berger redefined our understanding of the geometry of DNA replication and was recognized with several honors, including the Nicholas Cozzarelli and Harold Weintraub awards. His work as a Jane Coffin Childs postdoctoral fellow at the University of Washington culminated in the world’s first computationally designed de novo protein interaction and a protein-based inhibitor to treat flu. Corn began his independent research career as a group leader at Genentech, where his lab discovered biological mechanisms for challenging therapeutic targets. He then moved back to academia as the founding scientific director of the Innovative Genomics Institute and faculty at UC Berkeley.
Corn’s research aims to better understand and treat disease through next-generation genome editing technologies. His research takes a multidisciplinary approach, combining cellular biochemistry, functional genomics, computational biology, bioengineering, and biophysics. His lab’s current focus is the development of genome editing, the mechanisms by which cells repair their DNA, and the maintenance of healthy organelles.
‘s projects
Unbiased Discovery of Heterogeneous DNA Repair Preferences
The DNA in our cells is damaged every time we go out in the sun, drink a glass of wine or even just sit perfectly still while our cells divide. To combat this threat, eukaryotes have evolved a dizzying number of ways to fix DNA damage, called the DNA-damage response (DDR). This complex, collective set […]
NOMIS researcher
Project period
2021 – 2026
Professorship of Genome Biology, ETH Zurich
Clinicians’ approaches to the prevention and treatment of diseases such as cancer, diabetes and heart disease are beginning to experience a shift from evidence-based medicine to personalized medicine. We now can perform genetic tests in order to determine if a person is susceptible to developing a particular disease as well as what response a person might […]
NOMIS researcher
Project period
2017 – 2027
‘s publications
FOXP3 expression depends on cell-type-specific cis-regulatory elements and transcription factor circuitry
FOXP3 is a lineage-defining transcription factor (TF) for immune-suppressive regulatory T cells (Treg cells). Although mice exclusively express FOXP3 in Treg cells, stimulated conventional CD4+ T cells (Tconv cells) also transiently express FOXP3 in humans. Mechanisms governing these distinct expression patterns need elucidation. Here, we performed CRISPR screens tiling the FOXP3 locus and targeting TFs in human Treg and Tconv cells to identify cis-regulatory elements (CREs) and trans-regulators of FOXP3. Tconv cell FOXP3 expression depended on a subset of Treg cell CREs, as well as Tconv-cell-selective positive (NS+) and negative (NS−) CREs. Combinatorial silencing of Tconv cell CREs revealed their epistatic logic. These CREs are occupied and regulated by TFs that we identified as FOXP3 regulators. Finally, mutagenesis of murine NS− CRE revealed its essentiality for restricting FOXP3 expression to Treg cells. We map CRE and TF circuitry to reveal distinct cell- and species-specific regulation of FOXP3 expression.
Research Fields
Biochemistry & Molecular Biology, Biomedical Research, Clinical Medicine, Health Sciences, Immunology
WEE1 inhibitors synergise with mRNA translation defects via activation of the kinase GCN2
Inhibitors of the protein kinase WEE1 have emerged as promising agents for cancer therapy. In this study, we uncover synergistic interactions between WEE1 small-molecule inhibitors and defects in mRNA translation, mediated by activation of the integrated stress response (ISR) through the kinase GCN2. Using a pooled CRISPRi screen, we identify GSPT1 and ALKBH8 as factors whose depletion confer hypersensitivity to the WEE1 inhibitor, AZD1775. We demonstrate that this synergy depends on ISR activation, which is induced by the off-target activity of WEE1 inhibitors. Furthermore, PROTAC-based WEE1 inhibitors and molecular glues show reduced or no ISR activation, suggesting potential strategies to minimise off-target toxicity. Our findings reveal that certain WEE1 inhibitors elicit dual toxicity via ISR activation and genotoxic stress, with ISR activation being independent of WEE1 itself or cell-cycle status. This dual mechanism highlights opportunities for combination therapies, such as pairing WEE1 inhibitors with agents targeting the mRNA translation machinery. This study also underscores the need for more precise WEE1 targeting strategies to mitigate off-target effects, with implications for optimising the therapeutic potential of WEE1 inhibitors.
Research Fields
Biology, Biomedical Research, Genetics & Heredity, Health Sciences, Molecular Biology, Natural Sciences
Targeted DNA ADP-ribosylation triggers templated repair in bacteria and base mutagenesis in eukaryotes
Base editors create precise genomic edits by directing nucleobase deamination or removal without inducing double-stranded DNA breaks. However, a vast chemical space of other DNA modifications remains to be explored for genome editing. Here we harness the bacterial antiphage toxin DarT2 to append ADP-ribosyl moieties to DNA, unlocking distinct editing outcomes in bacteria versus eukaryotes. Fusing an attenuated DarT2 to a Cas9 nickase, we program site-specific ADP-ribosylation of thymines within a target DNA sequence. In tested bacteria, targeting drives homologous recombination, offering flexible and scar-free genome editing without base replacement or counterselection. In tested yeast, plant and human cells, targeting drives substitution of the modified thymine to adenine or a mixture of adenine and cytosine with limited insertions or deletions, offering edits inaccessible to current base editors. Altogether, our approach, called append editing, leverages the addition of chemical moieties to DNA to expand current modalities for precision gene editing.
Research Fields
Applied Sciences, Biochemistry & Molecular Biology, Biomedical Research, Biotechnology, Enabling & Strategic Technologies, Genetics & Heredity, Health Sciences, Microbiology
‘s news
April 11, 2025
How human cells repair damaged DNA
NOMIS Professor of Genome Biology Jacob Corn and fellow researchers at ETH Zurich have unravelled the complex network that cells use to repair their genetic material. By examining thousands upon thousands of genetic interactions, the team has discovered new vulnerabilities in cancer cells that could be exploited therapeutically in the future. Their findings were published […]
August 12, 2024
Method blocking TREX1 enzyme boosts CRISPR gene editing efficiency in hard-to-edit cells
NOMIS researcher Jacob Corn and colleagues have discovered that the enzyme TREX1 hinders the efficiency of CRISPR gene editing in certain cells. By blocking TREX1 or using protected DNA templates, the researchers were able to significantly improve gene editing, offering new strategies to enhance genome editing in challenging contexts. Their findings were published in Nature […]
NOMIS scientist Jacob Corn has published a study in the journal Cell: “A Genome-wide ER-phagy Screen Highlights Key Roles of Mitochondrial Metabolism and ER-Resident UFMylation.” A summary follows. Selective autophagy of organelles is critical for cellular differentiation, homeostasis, and organismal health. Autophagy of the endoplasmic reticulum (ER-phagy) is implicated in human neuropathy but is poorly […]
